The results indicated significantly higher APOL1 levels in breast invasive carcinoma, colon adenocarcinoma, HNSC, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, stomach adenocarcinoma and THCA (Figures 1B, C). This evidence concerns the gene APOL1 and invasive breast carcinoma.